Copaxone (Co-PAX-ohn, copolymer-1 or "cop-1")

September 1996

Patients with multiple sclerosis will be asking about Copaxone (Co-PAX-ohn, copolymer-1 or "cop-1"). An FDA committee will review it this month. They'll most probably advise approval for patients with relapsing forms of MS.

Copaxone suppresses the immune response that leads to neurological damage. It reduces relapse rates...and might slow disability.

We'll fill you in on more details when it gets approved.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote